Making sense of 'side effects': Counterpublic health in the era of direct-acting antivirals

被引:33
作者
Bryant, Joanne [1 ]
Rance, Jake [1 ]
Hull, Peter [1 ]
Mao, Limin [1 ]
Treloar, Carla [1 ]
机构
[1] Univ New South Wales, Ctr Social Res Hlth, Sydney, NSW 2052, Australia
关键词
Direct-acting antivirals; Hepatitis C; Side effects; Counterpublic health; HEPATITIS-C VIRUS; SUBSTITUTION THERAPY ANALYSIS; HCV GENOTYPE 1; DRUG-USERS; INFECTION; PEOPLE; SERVICES; EFFICACY; SAFETY; SOFOSBUVIR;
D O I
10.1016/j.drugpo.2019.06.002
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Direct-Acting Antiviral (DAA) treatments for hepatitis C have been widely promoted by health promotion professionals and medical clinicians as being 'side-effect free'. In this paper, we draw on data that troubles this approach. We used a mixed method design to collect data from people who inject drugs, and who were DAA treatment naive, in New South Wales, Australia. We describe knowledge about and perceptions of DAA treatment. We found that concerns about side effects were commonplace - for example, one-third (37%) of participants who had not taken up treatment worried "a lot" about 'side effects' - and that these concerns were underpinned by a general distrust and suspicion of medical institutions and their technologies, including widespread negative associations linked to interferon treatment. In trying to make sense of this, we draw on the concept of counterpublit health and its recognition that the everyday health needs, knowledges and aspirations of subordinated citizens frequently contradict the normative frameworks governing public health interventions. We suggest that failing to engage with concerns about 'side effects' could hinder elimination efforts. Our analysis suggests that addressing the issue of 'side effects' within the 'public' discourse of DAAs will not dampen or damage elimination efforts, as some might fear, but rather it will legitimate the concerns of people who inject, decrease their suspicion of medical interventions, and better support the uptake of DAA treatments.
引用
收藏
页码:77 / 83
页数:7
相关论文
共 44 条
[1]  
Allmark P, 2006, J MED ETHICS, V32, P460, DOI 10.1136/jme.2005.014035
[2]  
[Anonymous], 2018, Monitoring hepatitis C treatment uptake in Australia
[3]  
[Anonymous], EUR J PSYCHOTRAUM S1
[4]  
[Anonymous], 2021, GLOB PROGR REP HIV V
[5]  
[Anonymous], QUALITATIVE RES HLTH
[6]   Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis [J].
Asselah, Tarik ;
Kowdley, Kris V. ;
Zadeikis, Neddie ;
Wang, Stanley ;
Hassanein, Tarek ;
Horsmans, Yves ;
Colombo, Massimo ;
Calinas, Filipe ;
Aguilar, Humberto ;
de Ledinghen, Victor ;
Mantry, Parvez S. ;
Hezode, Christophe ;
Marinho, Rui Tato ;
Agarwal, Kosh ;
Nevens, Frederik ;
Elkhashab, Magdy ;
Kort, Jens ;
Liu, Ran ;
Ng, Teresa I. ;
Krishnan, Preethi ;
Lin, Chih-Wei ;
Mensa, Federico J. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2018, 16 (03) :417-426
[7]  
Australian Institute of Health and Welfare, 2017, NATL DRUG STRATEGY H
[8]   Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy [J].
Banerjee, D. ;
Reddy, K. R. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 43 (06) :674-696
[9]   Time to invest in a 'counterpublic health' approach: promoting sexual health amongst sexually active young people in rural Uganda [J].
Bell, Stephen A. ;
Aggleton, Peter .
CHILDRENS GEOGRAPHIES, 2012, 10 (04) :385-397
[10]   Measuring stigma in people with HIV: Psychometric assessment of the HIV stigma scale [J].
Berger, BE ;
Ferrans, CE ;
Lashley, FR .
RESEARCH IN NURSING & HEALTH, 2001, 24 (06) :518-529